SynBiotic SE

XETRA SBX.DE

SynBiotic SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 3.07 M

SynBiotic SE Net Cash Used Provided By Financing Activities is USD 3.07 M for the year ending December 31, 2023, a -40.59% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • SynBiotic SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 5.17 M, a -16.20% change year over year.
  • SynBiotic SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 6.16 M, a -39.69% change year over year.
  • SynBiotic SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 10.22 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
XETRA: SBX.DE

SynBiotic SE

CEO Mr. Daniel Kruse
IPO Date Jan. 7, 2021
Location Germany
Headquarters Innere Wiener Str. 14
Employees 55
Sector Health Care
Industries
Pharmaceuticals Biotechnology Cosmetics
Description

SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.

StockViz Staff

January 15, 2025

Any question? Send us an email